Merck (MRK) Up +34.5% Over Past Year: Q1 2026 Earnings Preview
Key Takeaways
- Analysts expect Q1 2026 revenue of $15.91 billion, up slightly from $15.5 billion in Q1 2025.
- Consensus earnings per share (EPS) estimate stands at -$1.31, reflecting acquisition-related charges.
- Keytruda oncology sales projected at $7.73 billion, driving overall growth.
- Full-year 2026 guidance includes revenue of $65.5-$67.0 billion and adjusted EPS of $5.00-$5.15.
- Investors watching pipeline updates, including recent Terns Pharmaceuticals acquisition, and Winrevair progress.
- Stock up 34.5% over the past year amid strong Keytruda demand.
Earnings Context: Why This Report Matters Now
MRK's Q1 2026 earnings, set for release on April 30, arrive at a critical moment for the pharmaceutical leader. Keytruda, the blockbuster PD-1 inhibitor, drives nearly half of sales, but its U.S. patent expiry in 2028 puts a spotlight on the need for growth and diversification. Recent quarters have demonstrated resilience, with Q4 2025 revenue coming in at $16.4 billion, beating estimates. In a landscape marked by generic competition and M&A costs, this report will shed light on pipeline strength, including launches like Winrevair for pulmonary hypertension. For investors like us, it provides key insights into maintaining momentum in oncology and vaccines—essential for long-term valuation in biotech.
Q1 Earnings Expectations
Wall Street looks for Q1 revenue of $15.91 billion, a 2.7% year-over-year increase driven by Keytruda and the animal health segment. The consensus GAAP EPS estimate is -$1.31, reflecting upfront costs from the Terns Pharmaceuticals acquisition announced in March. Adjusted figures, stripping out those charges, should remain stable and in line with full-year guidance.
Key areas to watch include Keytruda sales of $7.73 billion, building on prior quarters, along with progress on its subcutaneous formulation. Gross margins, R&D spending, and any adjustments to 2026 guidance will also draw scrutiny. MRK has a strong track record, beating EPS estimates in seven of the last eight quarters, with shares up 2.2% after Q4 2025 results. To gauge how MRK stacks up, I checked it against peers using Tickeron’s AI Screener.
Market Reaction and Investor Sentiment
Sentiment heading into earnings is cautiously optimistic. MRK shares are up 34.5% over the past year, outperforming the industry on Keytruda's strength, though patent cliff worries provide some balance. Options pricing suggests a ±4.15% move post-earnings. Potential downside could come from weaker vaccine sales or elevated deal costs, while stronger-than-expected Keytruda numbers might spark upside. Analysts hold a consensus Hold rating, with price targets around $125.
A Tool I Rely On: Tickeron’s AI Screener
In my research process, Tickeron’s AI Screener stands out as a powerful way to sift through stocks and ETFs. This AI-driven tool lets me filter based on technical patterns, fundamentals, trends, volatility, and signals, scanning thousands of names with custom criteria like industry, market cap, indicators, price patterns, and performance metrics. It uncovers trade ideas, trending stocks, breakouts, and opportunities faster than manual methods. I use it regularly to refine my watchlist and compare names like MRK—worth checking out to streamline your own workflow.
Forward Outlook and Key Factors to Monitor
Post-Q1, look for confirmation of 2026 guidance: revenue of $65.5-$67.0 billion and adjusted EPS of $5.00-$5.15, balancing Keytruda growth with acquisition integration. Keytruda's push into new indications and markets remains pivotal, with the subcutaneous version poised to improve accessibility.
Pipeline highlights include Winrevair's launch momentum and the Terns oncology assets. Keep an eye on margin pressures from R&D and manufacturing, plus animal health performance. Broader factors like biosimilar threats after 2028 and regulatory wins will influence the path forward. From what I see, tracking these quarterly updates will be crucial for spotting sustained growth.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MRK in upward trend: 10-day moving average crossed above 50-day moving average on May 28, 2026
The 10-day moving average for MRK crossed bullishly above the 50-day moving average on May 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on MRK as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on June 24, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
MRK moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in of 342 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 240 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MRK broke above its upper Bollinger Band on June 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.215) is normal, around the industry mean (19.568). P/E Ratio (32.530) is within average values for comparable stocks, (26.482). Projected Growth (PEG Ratio) (5.370) is also within normal values, averaging (15.849). Dividend Yield (0.029) settles around the average of (0.031) among similar stocks. P/S Ratio (4.376) is also within normal values, averaging (3.939).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
Advertisement